标题
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
作者
关键词
-
出版物
Cancers
Volume 12, Issue 6, Pages 1607
出版商
MDPI AG
发表日期
2020-06-18
DOI
10.3390/cancers12061607
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
- (2020) Laura Martin de la Fuente et al. VIRCHOWS ARCHIV
- Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer
- (2020) Paul Kubelac et al. Cancers
- Platinum Resistance in Ovarian Cancer: Role of DNA Repair
- (2019) Giovanna Damia et al. Cancers
- Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
- (2019) Ainhoa Madariaga et al. Cancers
- Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
- (2019) Elizabeth L. Christie et al. Nature Communications
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
- (2019) Xuan Jiang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers
- (2019) Katia A. Mesquita et al. GYNECOLOGIC ONCOLOGY
- Evolve: A post PARP inhibitor clinical translational phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.
- (2019) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.
- (2019) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
- (2019) Alanna R. Kaplan et al. Science Translational Medicine
- First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematological Cancers: Results of a Phase I Dose Escalation Study
- (2019) Amit Khot et al. Cancer Discovery
- What “The Cancer Genome Atlas” database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs
- (2019) Oscar Briz et al. Expert Opinion on Drug Metabolism & Toxicology
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status
- (2019) Federica Tomao et al. CANCER TREATMENT REVIEWS
- Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells
- (2019) Markus Kleih et al. Cell Death & Disease
- A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
- (2019) Amit M. Oza et al. CLINICAL CANCER RESEARCH
- High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome
- (2019) Dominik Wolf et al. INTERNATIONAL JOURNAL OF CANCER
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- Harnessing DNA Double-Strand Break Repair for Cancer Treatment
- (2019) Anika Trenner et al. Frontiers in Oncology
- The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility
- (2018) Zhiguang Zhao et al. BIOSCIENCE REPORTS
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
- (2018) Rajat Gupta et al. CELL
- The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
- (2018) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer
- (2018) Laureen S. Ojalvo et al. HUMAN PATHOLOGY
- Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy
- (2018) Yue-Qin Li et al. IUBMB LIFE
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- DNA damage repair in ovarian cancer: unlocking the heterogeneity
- (2018) Mary Ellen Gee et al. Journal of Ovarian Research
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.
- (2018) Geraldine Helen O'Sullivan Coyne et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
- (2018) Joyce F. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap
- (2018) Jeanna M McCuaig et al. JOURNAL OF MEDICAL GENETICS
- The shieldin complex mediates 53BP1-dependent DNA repair
- (2018) Sylvie M. Noordermeer et al. NATURE
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
- (2018) Kevin M. Foote et al. JOURNAL OF MEDICINAL CHEMISTRY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein
- (2018) Brian Kawahara et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer
- (2017) Tailin Li et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
- (2017) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- PARPi focus the spotlight on replication fork protection in cancer
- (2017) Katharina Schlacher NATURE CELL BIOLOGY
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
- (2017) Lu Yang et al. Science Translational Medicine
- Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
- (2017) Susan M. Domchek Cancer Discovery
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
- (2017) Sergey Karakashev et al. Cell Reports
- A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).
- (2017) D. Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease
- (2016) M. K. Wilson et al. ANNALS OF ONCOLOGY
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
- (2016) Hui Zhang et al. CELL
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
- (2015) B Colmegna et al. BRITISH JOURNAL OF CANCER
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
- (2015) R. Ceccaldi et al. CANCER RESEARCH
- Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition
- (2015) A. P. Wiegmans et al. MOLECULAR CANCER THERAPEUTICS
- Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
- (2015) Rémi Buisson et al. MOLECULAR CELL
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- High-throughput sequencing of DNA G-quadruplex structures in the human genome
- (2015) Vicki S Chambers et al. NATURE BIOTECHNOLOGY
- Decitabine reactivated pathways in platinum resistant ovarian cancer
- (2015) Fang Fang et al. Oncotarget
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
- (2014) Nikola A. Bowden CANCER LETTERS
- Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression
- (2014) KARINA DAHL STEFFENSEN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- PARP Inhibitors as P-glyoprotein Substrates
- (2014) Denise Lawlor et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
- (2014) Gottfried E. Konecny et al. JNCI-Journal of the National Cancer Institute
- A Polymerase Theta-dependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites
- (2014) Wouter Koole et al. Nature Communications
- Wee1 kinase as a target for cancer therapy
- (2013) Khanh Do et al. CELL CYCLE
- Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
- (2013) Sofia Santos et al. CURRENT CANCER DRUG TARGETS
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study
- (2012) Jennifer M. Rubatt et al. GYNECOLOGIC ONCOLOGY
- A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
- (2012) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer
- (2012) Don S. Dizon et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair
- (2012) Samuel F. Bunting et al. MOLECULAR CELL
- Small-molecule–induced DNA damage identifies alternative DNA structures in human genes
- (2012) Raphaël Rodriguez et al. Nature Chemical Biology
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study
- (2011) Chunqiao Tian et al. GYNECOLOGIC ONCOLOGY
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
- (2010) Sanjeevani Arora et al. DNA REPAIR
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma
- (2010) Natini Jinawath et al. PLoS One
- Chk1 promotes replication fork progression by controlling replication initiation
- (2010) E. Petermann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
- (2009) Meng Li et al. BMC Medical Genomics
- Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
- (2009) T. Hay et al. CANCER RESEARCH
- Role of TLS DNA polymerases eta and kappa in processing naturally occurring structured DNA in human cells
- (2009) Rémy Bétous et al. MOLECULAR CARCINOGENESIS
- A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency
- (2009) Liu Cao et al. MOLECULAR CELL
- Relationship BetweenERCC1Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer
- (2008) Thomas C. Krivak et al. JOURNAL OF CLINICAL ONCOLOGY
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now